Combination therapies for treating cancer

A therapy, technology for cancer

Pending Publication Date: 2020-02-21
特沙诺有限公司 +1
View PDF11 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, no new safety signals were identified

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapies for treating cancer
  • Combination therapies for treating cancer
  • Combination therapies for treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0280] Example 1 - Combination of Low Doses of PARP Inhibiting Agents with Agents Inhibiting PD-1 Signaling Induces Synergistic Antitumor Activity

[0281] Tumor Inoculation and Treatment Protocols

[0282] C57BL / 6 mice were inoculated subcutaneously under the right flank from Apc Min The mSK6005 fragment of a primary murine skin cancer model developed on a / J heterozygous background (R2P4, 2-4 mm in diameter) was used for tumor development. When the average tumor size reaches 148mm 3 At , mice were randomly selected and treatment started.

[0283] Mice were divided into six groups and treated with niraparib, anti-PD-1 (Bio X cells, New Hampshire), vehicle (containing 0.5% methylcellulose), or PD-1 isoforms (Bio X cells, New Hampshire )deal with. Specifically, the treatment regimen for each group is described in Table 2.

[0284] Table 2: Treatment schedule for each group.

[0285]

[0286] All procedures related to animal handling, care, and treatment in this study w...

Embodiment 2

[0288] Example 2 - Treatment of Cancer with Combinations of PARP Inhibitors and Anti-PD-1 Agents

[0289] This Example describes a multicenter, open-label, single-arm Phase 1 / 2 study evaluating the safety and efficacy of combination therapy with a PARP inhibitor (niraparib) and an anti-PD-1 agent (pembrolizumab).

[0290] Inclusion criteria

[0291] To be eligible for this study, patients must have histologically documented advanced (unresectable) metastatic cancer. Specifically, patients with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer, which are exemplary gynecologic cancers, who have recurrent disease and have been previously treated for advanced / metastatic disease, and who respond to First-line platinum-based therapy experiences responses lasting at least 6 months, but is currently considered platinum-resistant and eligible for combination therapy treatment as described herein.

[0292] Administration of Exemplary Agents that Inhibit PARP

[...

Embodiment 3

[0303] Example 3 - Clinical Dose-Discovery Combination Study of PARP Inhibitors and Anti-PD-1 Agents for the Treatment of Cancer

[0304] The following examples describe Phase 1 findings and Phase 2 interim findings of a clinical study designed to evaluate combination therapy with niraparib and an anti-PD-1 agent (pembrolizumab) (TOPACIO; NCT02657889).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods of treatment for recurrent cancer(s) through combination therapy with an agent that inhibits programmed death- 1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of the following U.S. provisional application serial numbers: 62 / 503,879 filed May 9, 2017, 62 / 508,359 filed May 18, 2017, 62 / 556,255 filed September 8, 2017, 2018 62 / 634,789 filed February 23, 62 / 646,332 filed March 21, 2018, and 62 / 648,327 filed March 26, 2018, the contents of which are hereby incorporated by reference in their entirety. [0003] Submission of a sequence listing as an ASCII text file [0004] The content of the following submission regarding the ASCII text file is hereby incorporated by reference in its entirety: Computer Readable Form of the Sequence Listing (CRF) (File Name: 757822000140SEQLIST.TXT, Date of Record: May 9, 2018, Size: 10 KB). [0005] background [0006] Cancer is a serious public health problem, according to American Cancer Society, Cancer Facts & Figures 2016 (http: / / www.cancer.org / acs / groups / content / @research / documents / document / acspc-047079.pdf) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K39/00A61K39/395A61P35/00A61P35/04
CPCA61P35/04A61P35/00C07K16/2818A61K2039/545A61K2039/505A61K2039/55A61K9/0019A61K31/454A61P35/02A61K39/395A61K2300/00A61K39/3955A01K1/01G06T7/215H01R13/516A61K48/00A61K6/00
InventorD.波比列夫B.德祖贝P.孙A.R.弗格森
Owner特沙诺有限公司